Skip to content
  • About us
    • Mission & Strategy
    • Our story
    • Our team
  • Inobrodib
    • Science
    • Clinical trials
    • Indications under investigation
    • For Physicians
    • For Patients
  • News
    • Press releases
    • Publications
  • Contact us
  • About us
    • Mission & Strategy
    • Our story
    • Our team
  • Inobrodib
    • Science
    • Clinical trials
    • Indications under investigation
    • For Physicians
    • For Patients
  • News
    • Press releases
    • Publications
  • Contact us
Linkedin

Category: Team

Applications

Inobrodib is currently being evaluated for safety and effectiveness in multiple specific settings

FDC40D06-9F76-4E8A-AF33-68251D6B17C1

Multiple Myeloma

Haematological malignancies, and specifically multiple myeloma (MM), are regulated in part by p300/CBP.
5ED9A5DB-1645-4854-AFCE-FF80DBBE114F
FDC40D06-9F76-4E8A-AF33-68251D6B17C1

Other Applications

Acute Myeloid Leukaemia (AML), Lymphomas, Solid tumours and Targeted Tumours.

8B1E0328-3F62-4701-A135-6606C5F74CC5
5ED9A5DB-1645-4854-AFCE-FF80DBBE114F

About CellCentric

CellCentric is a clinical stage biotech company focused on the development of a first of its kind, p300/CBP inhibitor to treat specific cancer types.

Quick Links

  • About us
  • Inobrodib
  • Clinical trials
  • Publications
  • Our story
Menu
  • About us
  • Inobrodib
  • Clinical trials
  • Publications
  • Our story
  • Our team
  • Press releases
  • News
  • Contact
  • Expanded Access Policy
  • Privacy Policy
Menu
  • Our team
  • Press releases
  • News
  • Contact
  • Expanded Access Policy
  • Privacy Policy

Follow us

Follow us and stay up to date with our latest news, events and scientific posters.

Icon-x Linkedin-in

© CellCentric Limited 2025 | Company #4948632

Main Menu
  • About us
    • Mission & Strategy
    • Our story
    • Our team
  • Inobrodib
    • Science
    • Clinical trials
    • Indications under investigation
    • For Physicians
    • For Patients
  • News
    • Press releases
    • Publications
  • Contact us
Follow us on LinkedIn